These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 18226005

  • 1. Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease.
    Perazella MA, Reilly RF.
    Semin Dial; 2008; 21(2):171-3. PubMed ID: 18226005
    [Abstract] [Full Text] [Related]

  • 2. Nephrogenic systemic fibrosis: a sufficient reason to avoid gadolinium-based contrast in all patients with renal impairment?
    Willicombe M, Cunningham J.
    Semin Dial; 2008; 21(2):140-1. PubMed ID: 18226007
    [Abstract] [Full Text] [Related]

  • 3. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 4. Nephrogenic systemic fibrosis and gadolinium-based contrast: what's a nephrologist to do?
    Perazella MA.
    Semin Dial; 2008; 21(2):121-2. PubMed ID: 18248521
    [No Abstract] [Full Text] [Related]

  • 5. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK.
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [Abstract] [Full Text] [Related]

  • 6. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients.
    Rodby RA.
    Semin Dial; 2008 May; 21(2):145-9. PubMed ID: 18226002
    [Abstract] [Full Text] [Related]

  • 7. Nephrogenic systemic fibrosis: a nephrologist's perspective.
    Saab G, Cheng S.
    Hemodial Int; 2007 Oct; 11 Suppl 3():S2-6. PubMed ID: 17897106
    [Abstract] [Full Text] [Related]

  • 8. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A.
    J Am Coll Radiol; 2008 Jan; 5(1):45-52. PubMed ID: 18180009
    [Abstract] [Full Text] [Related]

  • 9. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD, Bernheisel CR.
    Am Fam Physician; 2009 Oct 01; 80(7):711-4. PubMed ID: 19817341
    [Abstract] [Full Text] [Related]

  • 10. Nephrogenic systemic fibrosis: non-gadolinium options for the imaging of CKD/ESRD patients.
    Dawson P, Punwani S.
    Semin Dial; 2008 Oct 01; 21(2):160-5. PubMed ID: 18226006
    [Abstract] [Full Text] [Related]

  • 11. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA, Rodby RA.
    Semin Dial; 2007 Oct 01; 20(3):179-85. PubMed ID: 17555477
    [Abstract] [Full Text] [Related]

  • 12. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
    Heinrich M, Uder M.
    Rofo; 2007 Jun 01; 179(6):613-7. PubMed ID: 17497597
    [Abstract] [Full Text] [Related]

  • 13. [Nephrogenic systemic fibrosis].
    Breitschaft A, Stahlmann R.
    Med Monatsschr Pharm; 2009 Oct 01; 32(10):377-82. PubMed ID: 19886227
    [Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis and gadolinium-based contrast: medico-legal implications.
    Houck CM, Pristave RJ, Kannensohn KJ.
    Semin Dial; 2008 Oct 01; 21(2):166-70. PubMed ID: 18226003
    [Abstract] [Full Text] [Related]

  • 15. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
    Othersen JB, Maize JC, Woolson RF, Budisavljevic MN.
    Nephrol Dial Transplant; 2007 Nov 01; 22(11):3179-85. PubMed ID: 17890246
    [Abstract] [Full Text] [Related]

  • 16. Nephrogenic system fibrosis: a radiologist's practical perspective.
    Martin DR.
    Eur J Radiol; 2008 May 01; 66(2):220-4. PubMed ID: 18321672
    [Abstract] [Full Text] [Related]

  • 17. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS.
    Radiol Clin North Am; 2009 Sep 01; 47(5):871-5, vii. PubMed ID: 19744601
    [Abstract] [Full Text] [Related]

  • 18. Current status of gadolinium toxicity in patients with kidney disease.
    Perazella MA.
    Clin J Am Soc Nephrol; 2009 Feb 01; 4(2):461-9. PubMed ID: 19201920
    [Abstract] [Full Text] [Related]

  • 19. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR.
    Am J Kidney Dis; 2008 Jun 01; 51(6):966-75. PubMed ID: 18501784
    [Abstract] [Full Text] [Related]

  • 20. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].
    Hosoya T, Okada H, Horio M, Ohno I, Tamura S, Sugimoto H, Tsushima Y, Hayashi H, Fukuda K, Korogi Y, Yoshifumi N.
    Nihon Jinzo Gakkai Shi; 2009 Jun 01; 51(7):839-42. PubMed ID: 19928554
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.